ASG Fundamental Analysis - AURORA SPINE CORP

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ASG. ASG was compared to 15 industry peers in the Health Care Equipment & Supplies industry. ASG may be in some trouble as it scores bad on both profitability and health. ASG does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ASG has reported negative net income.

In the past year ASG had a positive cash flow from operations.

In the past 5 years ASG always reported negative net income.

The reported operating cash flow has been mixed in the past 5 years: ASG reported negative operating cash flow in multiple years.

1.2 Ratios

With an excellent Return On Assets value of -11.49%, ASG belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.

Looking at the Return On Equity, with a value of -35.06%, ASG belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-11.49%
ROE	-35.06%
ROIC	N/A

ROA(3y)-12.48%

ROA(5y)-12.6%

ROE(3y)-29.77%

ROE(5y)-27.75%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ASG has a better Gross Margin (59.74%) than 80.00% of its industry peers.

In the last couple of years the Gross Margin of ASG has grown nicely.

The Profit Margin and Operating Margin are not available for ASG so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	59.74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.72%

GM growth 5Y13.74%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ASG does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ASG has been increased compared to 1 year ago.

Compared to 5 years ago, ASG has more shares outstanding

The debt/assets ratio for ASG is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -0.06, we must say that ASG is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ASG (-0.06) is better than 80.00% of its industry peers.

A Debt/Equity ratio of 0.86 indicates that ASG is somewhat dependend on debt financing.

With a decent Debt to Equity ratio value of 0.86, ASG is doing good in the industry, outperforming 66.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.86
Debt/FCF	N/A
Altman-Z	-0.06

ROIC/WACCN/A

WACC6.73%

2.3 Liquidity

A Current Ratio of 1.94 indicates that ASG should not have too much problems paying its short term obligations.

ASG has a Current ratio of 1.94. This is amongst the best in the industry. ASG outperforms 93.33% of its industry peers.

ASG has a Quick Ratio of 1.10. This is a normal value and indicates that ASG is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.10, ASG belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.94
Quick Ratio	1.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ASG have decreased strongly by -105.95% in the last year.

ASG shows a small growth in Revenue. In the last year, the Revenue has grown by 6.76%.

The Revenue has been growing by 9.51% on average over the past years. This is quite good.

EPS 1Y (TTM)-105.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-300%

Revenue 1Y (TTM)6.76%

Revenue growth 3Y18.54%

Revenue growth 5Y9.51%

Sales Q2Q%-7.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASG. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ASG indicates a rather cheap valuation: ASG is cheaper than 86.67% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	143.59

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ASG!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

AURORA SPINE CORP

TSX-V:ASG (12/29/2025, 7:00:00 PM)

0.25

-0.01 (-1.96%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-19 2025-11-19

Earnings (Next)04-27 2026-04-27

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners25.17%

Ins Owner ChangeN/A

Market Cap19.30M

Revenue(TTM)18.05M

Net Income(TTM)-1.34M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.78
P/FCF	N/A
P/OCF	25.9
P/B	3.68
P/tB	4.5
EV/EBITDA	143.59

EPS(TTM)-0.02

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0

FCFYN/A

OCF(TTM)0.01

OCFY3.86%

SpS0.32

BVpS0.07

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-11.49%
ROE	-35.06%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	59.74%
FCFM	N/A

ROA(3y)-12.48%

ROA(5y)-12.6%

ROE(3y)-29.77%

ROE(5y)-27.75%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.72%

GM growth 5Y13.74%

F-Score4

Asset Turnover1.54

Health

		Industry Rank	Sector Rank
Debt/Equity	0.86
Debt/FCF	N/A
Debt/EBITDA	27.68
Cap/Depr	63.01%
Cap/Sales	3.67%
Interest Coverage	N/A
Cash Conversion	459.16%
Profit Quality	N/A
Current Ratio	1.94
Quick Ratio	1.1
Altman-Z	-0.06

F-Score4

WACC6.73%

ROIC/WACCN/A

Cap/Depr(3y)69.84%

Cap/Depr(5y)82.94%

Cap/Sales(3y)4.27%

Cap/Sales(5y)5.21%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-105.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-300%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)6.76%

Revenue growth 3Y18.54%

Revenue growth 5Y9.51%

Sales Q2Q%-7.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-103.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y85.71%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y307.04%

OCF growth 3YN/A

OCF growth 5Y319.03%

AURORA SPINE CORP / ASG.CA FAQ

What is the ChartMill fundamental rating of AURORA SPINE CORP (ASG.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ASG.CA.

What is the valuation status for ASG stock?

ChartMill assigns a valuation rating of 1 / 10 to AURORA SPINE CORP (ASG.CA). This can be considered as Overvalued.

How profitable is AURORA SPINE CORP (ASG.CA) stock?

AURORA SPINE CORP (ASG.CA) has a profitability rating of 3 / 10.

AURORA SPINE CORP (ASG.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AURORA SPINE CORP / ASG.CA FAQ

What is the ChartMill fundamental rating of AURORA SPINE CORP (ASG.CA) stock?

What is the valuation status for ASG stock?

How profitable is AURORA SPINE CORP (ASG.CA) stock?